Literature DB >> 17885627

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

Margalida Rotger1, Maria Saumoy, Kunlin Zhang, Markus Flepp, Roland Sahli, Laurent Decosterd, Amalio Telenti.   

Abstract

OBJECTIVE: To evaluate the possibility of copy number variation (CNV) of CYP2B6.
METHODS: We investigated CNV in 226 HIV-1-infected individuals by quantitative PCR. Identification of a candidate CNV prompted characterization of the size of deletion by assessment of absence of exons, mapping of the recombination site by sequencing, and by southern blot. The functional consequences of CNV were assessed in silico (predicted protein), and in vivo, by evaluation of plasma drug levels of the CYP2B6 substrate efavirenz.
RESULTS: Analyses identified one white individual carrying a heterozygous deletion of exons 1-4 of CYP2B6. We identified a approximately 68 kb deletion between CYP2B7 and CYP2B6, and mapped the crossover to a homologous region in intron 4 of both genes. The new hybrid allele, named CYP2B6*29, carries two amino acid substitutions, Q172H and M198T, previously associated with impaired enzyme function. Consistent with the functional prediction, the average of efavirenz area under the curve values of the patient was mean+/-SD, 81.64+/-23.62, versus 47.75+/-19.73 mug h/ml for individuals with an extensive metabolizer phenotype.
CONCLUSION: CYP2B6*29 represents a new mechanism of genetic variation at the CYP2B6 locus, underscoring the highly polymorphic nature of this isoenzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885627     DOI: 10.1097/FPC.0b013e3282ef5cd1

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  14 in total

1.  Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.

Authors:  Phumla Z Sinxadi; Paul D Leger; Helen M McIlleron; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens; David W Haas
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 2.  Mechanisms of change in gene copy number.

Authors:  P J Hastings; James R Lupski; Susan M Rosenberg; Grzegorz Ira
Journal:  Nat Rev Genet       Date:  2009-08       Impact factor: 53.242

3.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Authors:  Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.

Authors:  Paul Leger; Rebecca Dillingham; Carole Anne Beauharnais; Angela D M Kashuba; Naser L Rezk; Daniel W Fitzgerald; Jean William Pape; David W Haas
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

5.  Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Authors:  David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court
Journal:  J Antimicrob Chemother       Date:  2014-04-11       Impact factor: 5.790

Review 6.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

7.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Authors:  Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-12       Impact factor: 2.089

8.  Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.

Authors:  S Martis; H Mei; R Vijzelaar; L Edelmann; R J Desnick; S A Scott
Journal:  Pharmacogenomics J       Date:  2012-11-20       Impact factor: 3.550

9.  Genome wide analysis of chromosomal alterations in oral squamous cell carcinomas revealed over expression of MGAM and ADAM9.

Authors:  Vui King Vincent-Chong; Arif Anwar; Lee Peng Karen-Ng; Sok Ching Cheong; Yi-Hsin Yang; Padmaja Jayaprasad Pradeep; Zainal Ariff Abdul Rahman; Siti Mazlipah Ismail; Zuraiza Mohamad Zaini; Narayanan Prepageran; Thomas George Kallarakkal; Anand Ramanathan; Nur Aaina Binti Mohd Mohayadi; Nurul Shielawati Binti Mohamed Rosli; Wan Mahadzir Wan Mustafa; Mannil Thomas Abraham; Keng Kiong Tay; Rosnah Binti Zain
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Individualization of antiretroviral therapy.

Authors:  Rebecca Pavlos; Elizabeth J Phillips
Journal:  Pharmgenomics Pers Med       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.